We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Ingenuity Technology Licensed by SPRI

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Ingenuity has announced that Schering-Plough Research Institute has licensed both Ingenuity Pathways Analysis and the Ingenuity Pathways Analysis Integration Module (IPA-IM).

Ingenuity Pathways Analysis 3.0 (IPA) is designed to enable biologists and bioinformaticians to model, analyze, and understand the complex biological systems at the core of all life science research.

Ingenuity claims that, IPA leverages the world largest and highest quality knowledge base of biological networks and powerful algorithms, along with a software interface, to provide researchers with the insights and confidence needed to make better and faster decisions at every step of their research.

With access to the release of Ingenuity Pathways Analysis 3.0, scientists will now be able to integrate their own biological relationships with Ingenuity pathways to create custom networks for particular targets, biomarkers, disease areas, and processes and enable powerful computation and functional analysis.

Researchers will also benefit from Ingenuity Pathways Analysis 3.0's vastly expanded search capabilities and a doubling of the gene and disease content.